Blue Fin Capital’s GSK GSK Stock Holding History

Blue Fin Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,700	Closed	-$289K	–	131
2017 Q3	$289K	Sell	5,700 -160	-3%	-$8.12K	0.18%	112
2017 Q2	$315K	Sell	5,860 -624	-10%	-$33.3K	0.2%	109
2017 Q1	$342K	Sell	6,484 -1,120	-15%	-$56.8K	0.21%	104
2016 Q4	$366K	Buy	7,604 +244	+3%	+$12.1K	0.24%	98
2016 Q3	$397K	Buy	7,360 +224	+3%	+$12.3K	0.32%	84
2016 Q2	$387K	Hold	7,136	–	–	0.32%	83
2016 Q1	$362K	Sell	7,136 -964	-12%	-$48K	0.31%	83
2015 Q4	$409K	Sell	8,100 -120	-1%	-$6.12K	0.32%	85
2015 Q3	$395K	Sell	8,220 -360	-4%	-$18.7K	0.31%	85
2015 Q2	$447K	Buy	8,580 +1,540	+22%	+$86.7K	0.32%	86
2015 Q1	$406K	Hold	7,040	–	–	0.29%	93
2014 Q4	$376K	Buy	7,040 +476	+7%	+$26.6K	0.28%	90
2014 Q3	$377K	Buy	6,564 +172	+3%	+$10.5K	0.3%	89
2014 Q2	$427K	Hold	6,392	–	–	0.34%	84
2014 Q1	$427K	Sell	6,392 -60	-0.9%	-$4.06K	0.38%	78
2013 Q4	$431K	Buy	+6,452	New	+$418K	0.38%	78

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Blue Fin Capital's GSK Position: Q4 2017 in Review

Blue Fin Capital sold out of GSK (GSK) in Q4 2017, closing a stake of 5,700 shares — an estimated $289K sold.

Blue Fin Capital first reported a position in GSK in Q4 2013 and held it in 16 quarters. The position peaked at $447K in Q2 2015. 763 funds tracked by Wall St. Rank hold GSK as of Q4 2017.

Blue Fin Capital reported no remaining GSK position as of Q4 2017 after selling out during the quarter.
Blue Fin Capital sold 5,700 GSK shares in Q4 2017, an estimated $289K.
Blue Fin Capital first reported a position in GSK in Q4 2013 and held it in 16 quarters.
Blue Fin Capital's GSK position peaked at $447K in Q2 2015.
763 funds tracked by Wall St. Rank held GSK as of Q4 2017.

Based on Blue Fin Capital's 13F filing for Q4 2017, filed 26 Jan 2018.